KCG Holdings Inc. bought a new stake in shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) during the first quarter, Holdings Channel reports. The fund bought 20,306 shares of the biotechnology company’s stock, valued at approximately $106,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp boosted its position in Mirati Therapeutics by 22.9% in the first quarter. Bank of New York Mellon Corp now owns 63,004 shares of the biotechnology company’s stock valued at $328,000 after buying an additional 11,753 shares in the last quarter. Trexquant Investment LP boosted its position in Mirati Therapeutics by 62.2% in the first quarter. Trexquant Investment LP now owns 42,879 shares of the biotechnology company’s stock valued at $223,000 after buying an additional 16,447 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in Mirati Therapeutics during the first quarter valued at $677,000. Royce & Associates LP purchased a new position in Mirati Therapeutics during the first quarter valued at $692,000. Finally, Renaissance Technologies LLC purchased a new position in Mirati Therapeutics during the first quarter valued at $854,000. 64.38% of the stock is owned by institutional investors and hedge funds.

Mirati Therapeutics, Inc. (NASDAQ MRTX) traded up 1.05% during trading on Friday, reaching $4.80. 19,299 shares of the company’s stock were exchanged. The firm’s market cap is $119.85 million. Mirati Therapeutics, Inc. has a 12 month low of $2.70 and a 12 month high of $7.22. The firm’s 50-day moving average price is $4.30 and its 200-day moving average price is $4.53.

ILLEGAL ACTIVITY NOTICE: This article was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.dailypolitical.com/2017/08/11/kcg-holdings-inc-buys-shares-of-20306-mirati-therapeutics-inc-mrtx.html.

Several equities analysts recently weighed in on the stock. Jefferies Group LLC set a $5.00 target price on shares of Mirati Therapeutics and gave the company a “hold” rating in a research note on Friday, August 4th. ValuEngine cut shares of Mirati Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Zacks Investment Research cut shares of Mirati Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, May 4th. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $7.63.

Want to see what other hedge funds are holding MRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirati Therapeutics, Inc. (NASDAQ:MRTX).

Institutional Ownership by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.